Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Master Protocol for Mantle Cell Lymphoma A Multicenter Phase II Trial Testing Everolimus (RAD001) for the Treatment of Patients With Relapsed or Therapy Resistant Mantle Cell Lymphoma

NCT00516412 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT00516412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00516412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Master Protocol for Mantle Cell Lymphoma A Multicenter Phase II Trial Testing Everolimus (RAD001) for the Treatment of Patients With Relapsed or Therapy Resistant Mantle Cell Lymphoma
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2007
Completion date
August 31, 2012
Enrollment
35 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma